Abstract
Platinum-resistant ovarian cancer (PROC), defined as progression within 6 months from completion of platinum-containing therapy, is associated with poor prognosis. Tissue Factor (TF) is a novel target highly expressed in several solid tumors including ovarian cancer. Tisotumab vedotin (TV) is an investigational antibody-drug conjugate designed to bind to TF on target cells and to release monomethyl auristatin E (MMAE), a microtubule-disrupting agent, upon internalization resulting in cell cycle arrest and apoptotic cell death.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
